Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048080 | 1.00 | BRD4 (0.40) | BRD4POLBTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL7356670 | 0.74 | BRD4 (0.37) | BRD4POLBTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL4904965 | 0.70 | PDK1 (0.32) | — | |
| SCHEMBL12614403 | 0.69 | CHRM2 (0.43) | BRD4MEN1KMT2A | |
| SCHEMBL10211760 | 0.69 | BRD4 (0.46) | BRD4TSHRSMN1; SMN2GAA | |
| SCHEMBL3017696 | 0.67 | MMP2 (0.41) | BRD4POLBGAAKMT2A | |
| SCHEMBL11996941 | 0.67 | BRD4 (0.37) | BRD4POLBTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL2463944 | 0.67 | BRD4 (0.37) | BRD4POLBTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL4088779 | 0.67 | CHRNB2 (0.44) | BRD4 | |
| SCHEMBL4088784 | 0.67 | CHRNB2 (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657129-B2 | Cyclic amine compound and process for producing polyurethane resin by using it | TOSOH CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657129-B2 | Cyclic amine compound and process for producing polyurethane resin by using it | TOSOH CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2657237-B1 | CYCLIC AMINE COMPOUND, AND PROCESS FOR PRODUCING POLYURETHANE RESIN USING SAME | TOSOH CORP (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-20130289232-A1 | NOVEL CYCLIC AMINE COMPOUND AND PROCESS FOR PRODUCING POLYURETHANE RESIN BY USING IT | TOSOH CORPORATION (JP) | 2013-10-31 | — | — | US | disclosed |
| US-20130289232-A1 | NOVEL CYCLIC AMINE COMPOUND AND PROCESS FOR PRODUCING POLYURETHANE RESIN BY USING IT | TOSOH CORPORATION (JP) | 2013-10-31 | — | — | US | disclosed |
| EP-2657237-A1 | NOVEL CYCLIC AMINE COMPOUND, AND PROCESS FOR PRODUCING POLYURETHANE RESIN USING SAME | Tosoh Corporation (JP) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012086807-A1 | NOVEL CYCLIC AMINE COMPOUND, AND PROCESS FOR PRODUCING POLYURETHANE RESIN USING SAME | 東ソー株式会社 (JP) | 2012-06-28 | — | — | WO | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | BRD4 1087/4885POLB 923/4885TSHR 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.